Present studies have indicated that upon fusion with ELPs, the circulating half-life of PDs, including single-chain antibodies (anti-CD20 scFv, anti-CD99 scFv, anti-FLT3 scFv and anti-EGFR heavy-chain antibody) and therapeutic peptides (AP1 and p50), in the body increased significantly while inducing enhanced cytotoxic damage to the target tumor site or cell line [43,54,55]. The gene discussed is NFKB1; the disease is neoplasm.